In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

• Published in: Journal of antimicrobial chemotherapy Vol. 55; no. 6; pp. 950 - 953
• Main Authors: Guna, Remedios, Muñoz, Carlos, Domínguez, Victoria, García-García, Ángeles, Gálvez, Jorge, de Julián-Ortiz, Jesús-Vicente, Borrás, Rafael
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.06.2005; Oxford Publishing Limited (England)
• Subjects: Acetamides - pharmacology; Anti-Bacterial Agents - pharmacology; Antibiotics. Antiinfectious agents. Antiparasitic agents; antimycobacterial agents; Aza Compounds - pharmacology; Biological and medical sciences; broth microdilution method; Clarithromycin - pharmacology; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Linezolid; Medical sciences; Microbial Sensitivity Tests; Mycobacterium kansasii - drug effects; non-tuberculous mycobacteria; Oxazolidinones - pharmacology; Pharmacology. Drug treatments; Quinolines - pharmacology; Linezolid; Clarithromycin; Mycobacterial infection; Moxifloxacin; broth microdilution method; antimycobacterial agents; Fluoroquinolone derivatives; Bacteria; non-tuberculous mycobacteria; Oxazole derivatives; Clinical isolate; Quinolone derivatives; Human; Mycobacterium kansasii; Liquid medium; Method; Macrolide; In vitro; Biological activity; Infection; Antibiotic; Tuberculosis; Mycobacteriales; Oxazolidinone derivative; Bacteriosis; Mycobacteriaceae; Actinomycetes; Antibacterial agent
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dki111

Objectives: To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections. Results: The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC90 values of 0.125 mg/L. Linezolid was active against all isolates with MIC50 and MIC90 values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria. Conclusion: Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or intermittent therapy of M. kansasii lung disease.